$32.86+1.88 (+6.09%)
SpyGlass Pharma Inc. (SGP) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for SGP, including 2 SEC filings, 1 M&A update and 1 press release or news item. The most recent was published Oct 19, 2026.
Price$32.86+1.88 (+6.09%)
02:15 PM07:45 PM
News · 26 weeks160%
2026-05-032026-10-25
Mix990d
- SEC Filings4(44%)
- Other3(33%)
- Analyst1(11%)
- M&A1(11%)
Latest news
25 items- SECSEC Form 8-K filed by SpyGlass Pharma Inc.8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- PRSpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL SystemGroundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups86% of patients remained off all topical IOP-lowering drops90% of patients maintained ≥20/25 best corrected distance visual acuity (BCDVA)No product-related adverse events were reported IRVINE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines, today announced positive 4-year first-in-human (FIH) trial result
- SECSpyGlass Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- PRSpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion CapabilitySpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)Secures scalable commercial IOL manufacturing capacity for its Phase 3 lead product candidate, the BIM-IOL SystemAccelerates pathway to adding premium lens options into its IOL-based drug delivery systemSpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL material technology, such as Santen, Bausch + Lomb, and other global IOL companies IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Compa
- PRSpyGlass Pharma to Participate in Upcoming Investor ConferencesIRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Wells Fargo 21st Annual Healthcare ConferenceDate: Wednesday, September 9, 2026 Format: 1x1 Meetings only Citi’s 2026 Biopharma Back to School ConferenceDate: Thursday, September 10, 2026Time: 10:40 a.m. ETFormat: Fireside Chat and 1x1 Meetings H.C. Wainwright 28th Annual Global Investment ConferenceDate: Monday, September 14, 2026Time: 1:30 p.m. ETFormat: Corporate Presentation & 1x1 Meetings A live webcast and
- ANALYSTRaymond James initiated coverage on SpyGlass Pharma with a new price targetRaymond James initiated coverage of SpyGlass Pharma with a rating of Outperform and set a new price target of $39.00
- SECSEC Form 10-Q filed by SpyGlass Pharma Inc.10-Q - SpyGlass Pharma, Inc. (0001778922) (Filer)
- SECSpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- PRSpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesEnrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028. IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "We are plea
- PRSpyGlass Pharma Appoints Shannon Treviño as General CounselALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth. "We are delighted to welcome Shannon to our growing team. She is a proven leader with a track record of guiding complex organizations through periods of growth," said Patrick Mooney, CEO of SpyGlass Pharma. "The team we are building at SpyGlass is second to none, and I am confident that S
- PRSpyGlass Pharma Appoints Mike Pinder as Vice President, MarketingALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing. Mr. Pinder brings over 20 years of commercial launch experience in ophthalmology, focused on building, launching, and evolving significant brands, notably in the buy-and-bill specialty pharma model. At SpyGlass Pharma, he will build and lead the marketing function for the company as it continues to progress the Bimatoprost Drug Pad-IOL System (BIM-IOL System) through Phase 3 clinical trials and towards potential commercialization upon FDA approval. "We are thrilled t
- PRSpyGlass Pharma to Participate in Upcoming Investor ConferencesALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology ForumDate: Tuesday, May 26, 2026Time: 2:00 p.m. ETFormat: Fireside Chat Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Time: 2:35 p.m. ETFormat: Fireside Chat Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Time: 10:40 a.m. ETFormat: Corporate Presentation A live webcast and subsequent replay of each presentation can be ac
- PRSpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL SystemALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new add-on Category III CPT code for attachment and insertion of intraocular lens prosthesis-mounted drug-eluting implant, based on the application submitted for the Bimatoprost Drug Pad-IOL System (BIM-IOL System), in conjunction with established Category I cataract surgery procedure codes. "The approved Category III CPT code for attachment and insertion of the BIM-IOL System in conjunction with routine cataract surge
- SECSEC Form 10-Q filed by SpyGlass Pharma Inc.10-Q - SpyGlass Pharma, Inc. (0001778922) (Filer)
- SECSpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- PRSpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesEnrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Topline 12-month data from the BIM-IOL System Phase 1/2 trial demonstrated elimination of IOP-lowering topical eye drops for 98% of trial participants and 34% mean intraocular pressure (IOP) reduction from baseline at the intended commercial dose of 78-mcg, and all patients achieving best-corrected distance visual acuity (BCDVA) on par with state-of-the-art monofocal IOLs in the control group at 20/32 or better with a mean BCDVA equivalent to 20/20. Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to st
- SECSEC Form 10-K filed by SpyGlass Pharma Inc.10-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- SECSpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- PRSpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate UpdateSuccessfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) that demonstrated sustained intraocular pressure (IOP) control, elimination of IOP-lowering eye drops for 97% of trial participants, and improved visual performance, with a favorable safety profile.Phase 3 trials of BIM-IOL System are ongoing, with enrollment underway and full enrollment expected in 2027.Cash, cash equivalents and short-term investments expected to fund planned operations through 2028. ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- S
- ANALYSTH.C. Wainwright initiated coverage on SpyGlass Pharma with a new price targetH.C. Wainwright initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $37.00
- SECSpyGlass Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
- PRSpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating high quality of vision, performance in line with the state-of-the-art IOLs in the control groupOverall safety results were comparable to routine cataract surgery ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for th
- PRSpyGlass Pharma to Participate in the Jefferies Biotech on the Beach SummitALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026. About SpyGlass Pharma SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's mission is to significantly improve the lives of patients with chronic eye conditions by developing dur
- ANALYSTStifel initiated coverage on SpyGlass Pharma with a new price targetStifel initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $42.00
- ANALYSTCitigroup initiated coverage on SpyGlass Pharma with a new price targetCitigroup initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $42.00
SGP FAQ
7 questionsWhat is the latest news on SGP?
In the last 30 days Quantisnow tracked 4 wire items for SGP: 2 SEC filings, 1 M&A update and 1 press release or news item. The most recent was published on October 19, 2026.Where does SGP stock trade?
SpyGlass Pharma Inc. (SGP) is listed on NASDAQ.What sector and industry is SGP in?
SpyGlass Pharma Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did SpyGlass Pharma Inc. go public?
SpyGlass Pharma Inc. (SGP) completed its IPO in 2026.What are analysts saying about SGP?
SpyGlass Pharma Inc. has had 6 recent analyst actions on file. The most recent action was from Raymond James: Outperform with a $3900.00 price target on 2026-08-14. Recent price targets range from $3700.00 to $4200.00.What companies are similar to SGP?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare SGP side-by-side with any of them on Quantisnow.How can I track SGP on Quantisnow?
Quantisnow aggregates SpyGlass Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SGP to receive live email and push alerts on every new disclosure.